Eli Lilly and Company (NYSE:LLY) PT Raised to $850.00 at Truist Financial

Eli Lilly and Company (NYSE:LLYFree Report) had its target price boosted by Truist Financial from $650.00 to $850.00 in a report released on Wednesday morning, Benzinga reports. Truist Financial currently has a buy rating on the stock.

Other research analysts have also recently issued research reports about the company. BMO Capital Markets lifted their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an outperform rating in a research report on Wednesday. Morgan Stanley lifted their price target on Eli Lilly and Company from $763.00 to $805.00 and gave the company an overweight rating in a research note on Wednesday. UBS Group reissued a buy rating and set a $710.00 price target (up from $612.00) on shares of Eli Lilly and Company in a research note on Friday, October 20th. TheStreet lowered Eli Lilly and Company from a b rating to a c+ rating in a research note on Monday, December 4th. Finally, Wells Fargo & Company lifted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an overweight rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of Moderate Buy and a consensus target price of $621.81.

Get Our Latest Stock Report on LLY

Eli Lilly and Company Stock Up 2.8 %

Shares of NYSE LLY opened at $724.91 on Wednesday. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.82 and a current ratio of 1.05. Eli Lilly and Company has a 52 week low of $309.20 and a 52 week high of $742.00. The stock has a market capitalization of $688.16 billion, a P/E ratio of 131.32, a PEG ratio of 2.29 and a beta of 0.32. The stock’s fifty day moving average is $614.01 and its 200 day moving average is $577.12.

Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 48.12% and a net margin of 15.55%. The company had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter last year, the business earned $2.09 earnings per share. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. Sell-side analysts forecast that Eli Lilly and Company will post 6.34 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Investors of record on Thursday, February 15th will be issued a dividend of $1.30 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.13. The ex-dividend date is Wednesday, February 14th. This represents a $5.20 dividend on an annualized basis and a yield of 0.72%. Eli Lilly and Company’s dividend payout ratio is 81.88%.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 1,180 shares of the company’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $645.60, for a total value of $761,808.00. Following the transaction, the insider now directly owns 99,542,630 shares in the company, valued at approximately $64,264,721,928. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last quarter, insiders have sold 195,055 shares of company stock valued at $125,254,657. Corporate insiders own 0.13% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

A number of institutional investors have recently added to or reduced their stakes in the business. Partnership Wealth Management LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $14,010,000. Avantax Advisory Services Inc. increased its position in shares of Eli Lilly and Company by 2.4% during the 4th quarter. Avantax Advisory Services Inc. now owns 37,374 shares of the company’s stock valued at $21,786,000 after purchasing an additional 881 shares during the last quarter. Ieq Capital LLC increased its position in shares of Eli Lilly and Company by 7.7% during the 4th quarter. Ieq Capital LLC now owns 45,037 shares of the company’s stock valued at $26,253,000 after purchasing an additional 3,205 shares during the last quarter. Private Portfolio Partners LLC increased its position in shares of Eli Lilly and Company by 1.8% during the 4th quarter. Private Portfolio Partners LLC now owns 2,667 shares of the company’s stock valued at $1,555,000 after purchasing an additional 48 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Eli Lilly and Company by 0.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,395,896 shares of the company’s stock valued at $1,979,508,000 after purchasing an additional 28,104 shares during the last quarter. 81.38% of the stock is currently owned by institutional investors.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading

Analyst Recommendations for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.